[{"data":1,"prerenderedAt":202},["ShallowReactive",2],{"drug-fondaparinux":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":44,"contraindications":103,"warnings":113,"renal":121,"monitoring":122,"interactions":123,"review":124,"examples":126,"atc":136,"iran":138,"usApproval":145,"links":151,"populations":168},"fondaparinux",1,{"fa":7,"en":8},"فونداپارینوکس","Fondaparinux","blood",{"fa":11,"en":12},"مهارکننده غیرمستقیم فاکتور Xa","Indirect factor Xa inhibitor",[14],{"name":15,"market":16},"Arixtra","US",[18,19,7],"arixtra","آریکسترا",[21,35],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"syr-25","injection","sc","2.5 mg\u002F0.5 mL prefilled syringe",{"amount":27,"unit":28,"perVolumeMl":29},2.5,"mg",0.5,[16],[32],{"source":33,"section":34},"fda-fondaparinux","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":41,"refs":42},"syr-75","7.5 mg\u002F0.6 mL prefilled syringe (also 5 mg\u002F0.4 mL, 10 mg\u002F0.8 mL)",{"amount":39,"unit":28,"perVolumeMl":40},7.5,0.6,[16],[43],{"source":33,"section":34},[45,74],{"id":46,"disease":47,"label":48,"population":51,"type":56,"unit":28,"dose":57,"refs":58,"durationDays":63,"allowedFormulations":66,"notes":67},"proph","dvt-prophylaxis",{"fa":49,"en":50},"پیشگیری از DVT پس از جراحی شکستگی لگن، تعویض مفصل یا جراحی شکم — ۲٫۵ mg یک بار در روز","DVT prophylaxis after hip fracture, hip\u002Fknee replacement or abdominal surgery — 2.5 mg once daily",{"minAge":52,"minWeightKg":55},{"value":53,"unit":54},18,"year",50,"fixed",{"perDose":27,"dosesPerDay":5},[59,61],{"source":33,"section":60},"2.2",{"source":33,"section":62},"2.3",{"min":64,"max":65},5,9,[22],[68],{"text":69,"refs":72},{"fa":70,"en":71},"اولین دوز ۶ تا ۸ ساعت پس از جراحی پس از هموستاز (زودتر خونریزی بیشتر). شکستگی لگن: تا ۲۴ روز اضافه.","First dose 6–8 h after surgery once haemostasis is established (earlier increases bleeding). Hip fracture: up to 24 additional days.",[73],{"source":33,"section":60},{"id":75,"disease":76,"label":77,"population":80,"type":82,"unit":28,"dose":83,"refs":93,"notes":96},"tx","venous-thromboembolism",{"fa":78,"en":79},"درمان DVT و PE — زیر ۵۰ kg: ۵؛ ۵۰ تا ۱۰۰: ۷٫۵؛ بالای ۱۰۰ kg: ۱۰ mg یک بار در روز","DVT and PE treatment — \u003C50 kg: 5; 50–100: 7.5; >100 kg: 10 mg once daily",{"minAge":81},{"value":53,"unit":54},"weightBand",{"weightBands":84},[85,88,90],{"minWeightKg":86,"maxWeightKg":87,"perDose":64,"dosesPerDay":5},0,49.99,{"minWeightKg":87,"maxWeightKg":89,"perDose":39,"dosesPerDay":5},100,{"minWeightKg":89,"maxWeightKg":91,"perDose":92,"dosesPerDay":5},null,10,[94],{"source":33,"section":95},"2.4",[97],{"text":98,"refs":101},{"fa":99,"en":100},"وارفارین هرچه زودتر (معمولاً ظرف ۷۲ ساعت) شروع شود؛ دست‌کم ۵ روز و تا INR ۲ تا ۳ دو روز پشت سر هم.","Start warfarin as soon as possible (usually within 72 h); at least 5 days and until INR 2–3 on two consecutive days.",[102],{"source":33,"section":95},[104],{"id":105,"severity":106,"text":107,"refs":110},"ci","block",{"fa":108,"en":109},"ClCr زیر ۳۰؛ خونریزی فعال شدید؛ اندوکاردیت باکتریایی؛ ترومبوسیتوپنی با آنتی‌بادی ضدپلاکت وابسته به فونداپارینوکس؛ وزن زیر ۵۰ kg در پیشگیری؛ حساسیت.","CrCl \u003C30; active major bleeding; bacterial endocarditis; thrombocytopenia with a positive anti-platelet antibody test in the presence of fondaparinux; body weight \u003C50 kg for prophylaxis; hypersensitivity.",[111],{"source":33,"section":112},"4",[114],{"text":115,"refs":118},{"fa":116,"en":117},"هشدار جعبه‌ای: هماتوم نخاعی یا اپیدورال با بی‌حسی نخاعی یا پونکسیون (فلج طولانی یا دائمی).","Boxed warning: spinal or epidural haematoma with neuraxial anaesthesia or puncture (long-term or permanent paralysis).",[119],{"source":33,"section":120},"Boxed Warning",[],[],[],{"status":125,"reviewer":91,"date":91},"unverified",[127,131],{"regimen":46,"formulation":22,"input":128,"expect":130},{"ageYears":129,"weightKg":129},70,{"perDose":27,"mlPerDose":29},{"regimen":75,"formulation":36,"input":132,"expect":135},{"ageYears":133,"weightKg":134},55,80,{"perDose":39,"mlPerDose":40},[137],"B01AX05",{"status":139,"refs":140},"not-found",[141],{"source":142,"section":143,"url":144},"darooyab-generic","G-1688\u002FFondaparinux","https:\u002F\u002Fwww.darooyab.ir\u002FG-1688\u002FFondaparinux",{"kind":146,"refs":147,"id":150},"NDA authorized generic",[148],{"source":33,"section":149},"SPL approval \u002F marketing category","NDA021345",[152,155,159,163,166],{"kind":153,"url":154,"label":150},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=021345",{"kind":156,"url":157,"label":158},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=4b65f642-87f7-4da5-a9c9-02cd1f8d9d16","FDA Fondaparinux",{"kind":160,"url":161,"label":162},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa612026.html","Fondaparinux Injection",{"kind":164,"url":165,"label":137},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=B01AX05",{"kind":167,"url":144,"label":8},"darooyab",{"pregnancy":169,"lactation":178,"pediatric":186,"geriatric":194},{"level":170,"text":171,"quote":174,"refs":175},"caution",{"fa":172,"en":173},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Available data from published literature and postmarketing reports have not reported a clear association with fondaparinux sodium and adverse developmental outcomes.",[176],{"source":33,"section":177},"8.1",{"level":170,"text":179,"quote":182,"refs":183},{"fa":180,"en":181},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of fondaparinux sodium in human milk, or the effects on milk production.",[184],{"source":33,"section":185},"8.2",{"level":170,"text":187,"quote":190,"refs":191},{"fa":188,"en":189},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of fondaparinux sodium for the treatment of venous thromboembolism have been established in pediatric patients aged 1 year and older weighing at least 10 kg.",[192],{"source":33,"section":193},"8.4",{"level":170,"text":195,"quote":198,"refs":199},{"fa":196,"en":197},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","When using fondaparinux sodium in elderly patients, pay particular attention to dosing directions and concomitant medications (especially anti-platelet medication) [see Warnings and Precautions (5.2) ] .",[200],{"source":33,"section":201},"8.5",1792156179447]